



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/834,410	04/12/2001	Toyohiro Sawada	019941-000510US	3651
20350	7590	05/27/2009		
TOWNSEND AND TOWNSEND AND CREW, LLP TWO EMBARCADERO CENTER EIGHTH FLOOR SAN FRANCISCO, CA 94111-3834			EXAMINER	
			YOUNG, MICAH PAUL	
			ART UNIT	PAPER NUMBER
			1618	
			MAIL DATE	DELIVERY MODE
			05/27/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No. 09/834,410	Applicant(s) SAWADA ET AL.
	Examiner MICAH-PAUL YOUNG	Art Unit 1618

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
 - If no period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
 - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(o).

Status

- 1) Responsive to communication(s) filed on 17 February 2009.
 2a) This action is FINAL. 2b) This action is non-final.
 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1,3,5-7,13-21 and 24-36 is/are pending in the application.
 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
 5) Claim(s) _____ is/are allowed.
 6) Claim(s) 1,3,5-7,13-21 and 24-36 is/are rejected.
 7) Claim(s) _____ is/are objected to.
 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date _____ |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 2/17/09 has been entered.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1, 3, 5-7, 13-21, and 24-26 rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

The claims state that the core does not contain a hydrogel forming polymer, however part a) states that the core can comprise polyethylene glycol. Polyethylene glycol is a form of polyethylene oxide. The hydrogel-forming polymers are defined by the claims as at least one type of polyethylene oxide. Meaning that polyethylene glycol, being a form of polyethylene oxide, is also a hydrogel-forming polymer. This is confusing since hydrogel forming polymers are restricted in the same clause that allows for polyethylene glycol. It is unclear what exactly is present in the core and coating of the formulation. Correction and clarification is required.

Claim 28 and 29 recite the limitation "the second drug" in lines 1 and 2 of the claims respectively. There is insufficient antecedent basis for this limitation in the claim. The claims are based on a claim that explicitly forecloses the inclusion of a second drug. Clarification is required.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1, 3, 7, 14, 15, 21, 25, 27, 30, 33, 35, and 36 are rejected under 35 U.S.C. 102(b) as being anticipated by Giannini et al (USPN 4,925,675 hereafter '675). The claims are drawn to a controlled release formulation comprising a core and coating where the core comprises a filler compound and a drug, and the coating comprises a hydrophilic base and hydrogel forming polymer.

The '675 patent teaches a controlled release erythromycin formulation comprising an active core and a non active protective coating layer (abstract). Erythromycin is mixed with a binding agent such as polyethylene glycol and coated to a sucrose seed creating an active core (claim 1). The active core is coated with a protective layer comprising a mixture of polyethylene glycol and polyethylene oxide (claims 5). The drug is present in an approximate amount of 14-40% by weight, with the polyethylene glycol in the core present in an approximate amount from

1-4% and the polyethylene glycol and oxide present in approximate amounts of 28-48\$ and 52-72% respectively (claims 3 and 5).

Regarding the percentage erosion of the filler, it is the position of the Examiner that this percentage would be inherent to any filler meeting the limitations of the claims. Sucrose and lactose are named in the specification as capable and useful fillers, thus these filler, present in the prior art would act identically and erode to the given percentage. Applicant is invited to provide evidence as to how the sucrose of the instant claims would behave differently than the sucrose of the prior art. Further no temporal data is given regarding when or where the eroding takes place. Any filler will erode 40-90% given enough time in the digestive tract, regardless of coating and presentation.

Regarding the claim reciting the determination of the eroding percentage, it is the position of the Examiner that the limitations render the claim a product by process claim. The claim is drawn to a tablet, yet recited methods of determination. Also regarding the compression coated limitation, it is the position of the Examiner that such a limitation is merely a product by process limitation, describing the manner in which the tablet is formed. Applicant is reminded that regarding product-by-process claims, even though product-by-process claims are limited by and defined by the process, determination of patentability is based on the product itself. The patentability of a product does not depend on its method of production. If the product in the product-by-process claim is the same as or obvious from a product of the prior art, the claim is unpatentable even though the prior product was made by a different process.” *In re Thorpe*, 777 F.2d 695, 698, 227 USPQ 964, 966 (Fed. Cir. 1985).

For these reasons the claims are anticipated by the prior art.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

Claims 1, 3, 5-7, 13-21 and 24-36 are rejected under 35 U.S.C. 103(a) as being unpatentable over the combined disclosures of Giannini et al (USPN 4,925,675 hereafter '675) in view of Sako et al (EP 0 661 045 hereafter '045) and Taniguchi et al (EP 0 709 386 hereafter '386). The claims are drawn to a controlled release formulation comprising an inner core comprising a drug and fillers, and an outer layer comprising a mixture of polymers, where the drug of the inner core is not present.

As discussed above the '675 patent discloses a coated tablet comprising fillers and a combination of water soluble and swellable polymers in the coating. The reference is however silent to the specific fillers, and active agents of the instant claims. These fillers are well known in the art as shown in the '045 patent. Likewise the active agents are well known as seen in the '386 patent.

The '045 reference teaches a compression molded oral formulation comprising a core comprising a drug (pg. 3, lin. 1-29), along with solubilizers that help improve the solubility of the drug in water such as citric acid, tartaric acid, and polyethylene glycol (pg 3, lin. 30-43). The core is coated with a hydrogel formulation comprising a hydrophilic base such as polyethylene glycols (pg. 3, lin. 49-pg. 4, lin. 7) and hydrogel-forming polymers with viscosities not less than 1000 cps in 1% aqueous solution such as polyethylene oxides (pg. 4, lin. 8-51). The formulation can include hydrogel-forming polymers in the core such as hydroxypropylmethylcellulose (pg. 3, lin. 37). The formulation further includes yellow iron sesquioxide (pg. 13, lin. 10-15). The drugs include lidocaine, nicardipine, and quindine, agents that are all metabolized by CYP3A4 (pg. 3, lin. 5-25). Upon administration, water is absorbed into the core of the formulation during its stay in the upper intestine, essentially dissolving the core and releasing the drug slowly as it travels to the colon (pg 2, lin. 35-40). The drug is present in the formulation in concentrations from 80-85%, the hydrophilic base is present in concentration from 5-80%, the hydrogel-forming polymer is present in concentration greater than 16% and solubilizing agent that aids in water absorption into the core is present in concentrations from 15-90% (pg. 3 lin. 25-pg. 5, lin. 13). The formulation remains within the digestive tract for up to 12 hours and within that time the formulation dissolves 70-100% (figures). The reference establishes the level of skill in the art regarding specific fillers and their relation to compression coatings and hydrogel-forming compression tablets. The artisan of ordinary skill would have been able to include the fillers of the '045 reference into the '675 since both formulation disclose similar formulations.

The '386 patent discloses a fused benzazepine derivative, which can be useful as a vasopressin antagonist. The drug can be formulated into tablets using conventional excipients

Art Unit: 1618

such as sucrose, gelatin and hydroxypropylcellulose (pg. 27, lin. 23 – 37). The drug of the invention can be used in the treatment of various disorders ranging from cerebrovascular disease to renal disorders (pg. 23, lin. 24 – 44). A skilled artisan would be able to include the compound of '386 into the formulation of '675 since the '675 reference uses similar drugs to treat similar disorders.

Furthermore the claims differ from the reference by reciting various concentrations of the active ingredient(s). However, the preparation of various pharmaceutical compositions having various amounts of the active is within the level of skill of one having ordinary skill in the art at the time of the invention. It has also been held that the mere selection of proportions and ranges is not patentable absent a showing of criticality. *See In re Russell*, 439 F.2d 1228 169 USPQ 426 (CCPA 1971).

With these things in mind it would have been obvious to combine the prior art in order to provide a stable controlled release formulation with improved lower digestive tract release. Following the suggestions of the '675 patent to coat the core tablet with a mixture of polyethylene glycol and oxide, it would have been obvious to use the fillers of the '045 patent in order to provide proper release of the core active agents. It would have been obvious to substitute the active agent of the '386 patent into the combination. One of ordinary skill in the art would have been motivated to combine the suggestions and teachings of the prior art with an expected result of a stable controlled release formulation useful in alleviating undesirable drug interactions.

Response to Arguments

Applicant's arguments with respect to claims 1, 3, 5-7, 13-26, and 30-36 have been considered but are moot in view of the new ground(s) of rejection.

Correspondence

Any inquiry concerning this communication or earlier communications from the examiner should be directed to MICAH-PAUL YOUNG whose telephone number is (571)272-0608. The examiner can normally be reached on Monday-Friday 7:00-4:30; every other Monday off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael G. Hartley can be reached on 571-272-0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Michael G. Hartley/
Supervisory Patent Examiner, Art Unit 1618

/MICAH-PAUL YOUNG/

Application/Control Number: 09/834,410

Page 9

Art Unit: 1618

Examiner, Art Unit 1618